Lupin Gains FDA Nod for Sugammadex Injection, Expanding U.S. Hospital Portfolio — Lupin Pharmaceuticals, Inc.

Event summary

Lupin received FDA approval for its Abbreviated New Drug Application for Sugammadex Injection on July 30, 2026.
The product is bioequivalent to Merck's Bridion® and is indicated for reversing neuromuscular blockade in adults and pediatric patients aged 2+ undergoing surgery.
Lupin launched two formulations: 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials in the U.S.
The approval strengthens Lupin's position in the U.S. hospital market, where it already has a strong presence across multiple therapy areas.

The big picture

Lupin's FDA approval for Sugammadex Injection marks a strategic win in the competitive U.S. hospital market, where complex generics and bioequivalent drugs are increasingly critical to cost management. The move underscores Lupin's ability to leverage its global manufacturing and R&D capabilities to challenge established players like Merck. With over 26,000 employees and a presence in 100+ markets, the company is well-positioned to expand its footprint in high-value therapeutic areas.

What we're watching

Market Penetration: How quickly Lupin can capture market share from Merck's Bridion® in the U.S. hospital setting.
Regulatory Compliance: Whether Lupin can maintain regulatory compliance across its 15 global manufacturing sites as it scales production.
Execution Risk: The pace at which Lupin integrates this product into its existing U.S. hospital portfolio without operational disruptions.